MRTX1133 can be an exceptionally strong and selective KRASG12D inhibitor. It optimally fills the switch II pocket and extends 3 substituents to favorably interact with the protein. The K And clinical trials of mixture therapy with KRAS G12C inhibitors and immune checkpoint inhibitors are alr